Anavex Life Sciences (AVXL) Scheduled to Post Quarterly Earnings on Tuesday

Anavex Life Sciences (NASDAQ:AVXL) is set to post its quarterly earnings results before the market opens on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.13). During the same period in the previous year, the company earned ($0.17) EPS. On average, analysts expect Anavex Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Anavex Life Sciences Trading Up 0.3 %

AVXL stock traded up $0.02 on Monday, hitting $6.51. The company’s stock had a trading volume of 554,384 shares, compared to its average volume of 1,325,793. The stock has a market cap of $552.05 million, a price-to-earnings ratio of -12.99 and a beta of 0.63. The firm has a 50 day moving average of $4.77 and a two-hundred day moving average of $4.84. Anavex Life Sciences has a 1 year low of $3.25 and a 1 year high of $10.45.

Wall Street Analyst Weigh In

AVXL has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Anavex Life Sciences in a report on Thursday. EF Hutton Acquisition Co. I raised Anavex Life Sciences to a “strong-buy” rating in a report on Monday, July 22nd.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.